These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 5405572)

  • 21. Pharmacodynamics of 3, 4-dihydroxyphenylalanine (Dopa) in Parkinson's disease.
    Van Woert MH
    Conn Med; 1970 Jun; 34(6):401-5. PubMed ID: 5431103
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 23. Parkinson's disease: L-dopa treatment and handwriting area.
    Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 25. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 26. L-dopa and the patient with Parkinson's disease.
    Fangman A; O'Malley WE
    Am J Nurs; 1969 Jul; 69(7):1455-7. PubMed ID: 5192672
    [No Abstract]   [Full Text] [Related]  

  • 27. [Preliminary observations on the use of L-DOPA in the treatment of the akinetic symptoms of Parkinson's disease].
    Uriciuoli R; Nivoli GC
    Minerva Med; 1968 May; 59(43):2516-21. PubMed ID: 5664430
    [No Abstract]   [Full Text] [Related]  

  • 28. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 29. [Results of psychometic tests in 23 patients with Parkinson's disease after 6 months treatment with L-dopa].
    Barbizet J; Duizabo P; Pasquier M
    Rev Neurol (Paris); 1972 Aug; 127(2):311-3. PubMed ID: 4666638
    [No Abstract]   [Full Text] [Related]  

  • 30. The modifying influence of L-dopa on the physical therapy program in Parkinson's disease.
    Blonsky ER; Minnigh EC
    Prog Phys Ther; 1970; 1(1):55-74. PubMed ID: 5523796
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 32. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 33. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 34. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of Parkinson's disease with L-dopa. Preliminary considerations on 40 cases].
    Rigotti S; Angelini C; Battistin L; Denes F
    Riv Sper Freniatr Med Leg Alien Ment; 1970 Dec; 94(6):1516-26. PubMed ID: 5518765
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(1):130-5. PubMed ID: 5084387
    [No Abstract]   [Full Text] [Related]  

  • 37. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract]   [Full Text] [Related]  

  • 38. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

  • 39. [Preliminary results of the treatment with L-Dopa of 30 patients with Parkinsonism].
    Dumas R; Rahme M; Schott B
    J Med Lyon; 1971 Apr; 52(207):599-615. PubMed ID: 5136571
    [No Abstract]   [Full Text] [Related]  

  • 40. [The therapeutic association of L-dopa and amantadine. Preliminary results in a group of patients with Parkinson's disease].
    Gomirato G; Perfetti C
    Riv Neurobiol; 1970; 16(3):247-54. PubMed ID: 5518838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.